{"id":6095,"date":"2022-05-12T14:02:31","date_gmt":"2022-05-12T12:02:31","guid":{"rendered":"https:\/\/www.rapharm.eu\/en\/?p=6095"},"modified":"2022-05-16T09:56:13","modified_gmt":"2022-05-16T07:56:13","slug":"eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg","status":"publish","type":"post","link":"https:\/\/www.rapharm.eu\/en\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/","title":{"rendered":"EU: Two new guidelines have been published and approved by the MDCG"},"content":{"rendered":"<style type=\"text\/css\"><\/style>\n<p>Recently, two new guidelines, MDCG 2022-5 and MDCG 2022-6, were published on the website of the European Commission and approved by the Medical Devices Coordination Group (MDCG). The guidelines are drafted in collaboration with interested parties represented in the various groups and are not legally binding. They present a common understanding of how the MDR and IVDR should be applied in practice aiming at an effective and harmonised implementation of the legislation.<\/p>\n\n\n\n<p><a href=\"http:\/\/MDCG Guideline 2022-5 Guidance on borderline between medical devices and medicinal products under Regulation (EU) 2017\/745 on medical devices\">MDCG Guideline 2022-5 Guidance on borderline between medical devices and medicinal products under Regulation (EU) 2017\/745 on medical devices <\/a>(MDR) was issued on 26 April 2022. This guideline was established by Article 103 of MDR. It provides further explanations and examples clarifying provisions laid down in the MDR and Directive 2001\/83\/EC relating to medicinal products for human use (MPD) in order to support the uniform application of the MDR across the EU. The document starts with the general discussion of the borderline between medical devices and medicinal products, including relevant definitions and examples. Separate chapters are dedicated to herbal products, substance-based devices, and medical device\/medicinal product combinations.<\/p>\n\n\n\n<p><br><a href=\"https:\/\/ec.europa.eu\/health\/system\/files\/2022-05\/mdcg_2022-6.pdf\">MDCG Guideline 2022-6 Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR <\/a>was issued on 4 May 2022. This document explains the concept of \u2018significant changes in the design and intended purpose\u2019 under IVDR Article 110(3). It concerns manufacturers of devices that are compliant with Directive 98\/79\/EC (IVDD) and that are placed on the market or put into service after 26 May 2022 during the transition period in accordance with Article 110(3) IVDR, irrespective of whether or not those devices required notified body involvement under the IVDD.<\/p>\n\n\n\n<p><br> The conditions for the application of the transitional provisions in Article 110(3) IVDR are that the devices continue to comply with the IVDD and that there are no significant changes in the design or intended purpose of the device after the date of application of the IVDR. Therefore, it is important for manufacturers and notified bodies to have a clear understanding as to what changes to design or intended purpose would be considered \u2018significant\u2019 under Article 110(3) IVDR.<\/p>\n\n\n\n<p>The annex to the\ndocument contains a chards of design changes and changes of the intended purpose\nwhich may be considered \u2018significant\u2019 when interpreting the first sentence of\nIVDR Art. 110(3).<\/p>\n\n\n\n<p>Click <a href=\"https:\/\/ec.europa.eu\/health\/system\/files\/2022-04\/mdcg_2022-5_en_0.pdf\">here <\/a>and <a href=\"https:\/\/ec.europa.eu\/health\/system\/files\/2022-05\/mdcg_2022-6.pdf\">here<\/a> for more information.&nbsp;<\/p>\n\n\n\n<p><strong>Do you need additional knowledge or assistance in meeting\nthe requirements of MDR\/IVDR?<\/strong><\/p>\n\n\n\n<p>With the help of our <a href=\"https:\/\/www.rapharm.eu\/en\/actual-educations\/\">actual\neducations<\/a> and <a href=\"https:\/\/www.rapharm.eu\/en\/consulting-services\/\">consulting services<\/a>, we can help you meet the requirements of the MDR\/IVDR.<\/p>\n\n\n\n<p><strong>Resources:<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/ec.europa.eu\/health\/system\/files\/2022-04\/mdcg_2022-5_en_0.pdf\">MDCG Guideline 2022-5 Guidance\non borderline between medical devices and medicinal products under Regulation\n(EU) 2017\/745 on medical devices, web page EK, 26 April 2022<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/ec.europa.eu\/health\/document\/download\/14c2d8dd-8489-4db5-b035-1c174f17fb54_en?filename=mdcg_2022-6.pdf\">MDCG Guideline 2022-6\nGuidance on significant changes regarding the transitional provision under\nArticle 110(3) of the IVDR, web page EK, 4 May 2022<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recently, two new guidelines, MDCG 2022-5 and MDCG 2022-6, were published on the website of the European Commission and approved by the Medical Devices Coordination Group (MDCG). The guidelines are drafted in collaboration with interested parties represented in the various groups and are not legally binding. They present a common understanding of how the MDR&#8230;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45,30],"tags":[],"class_list":["post-6095","post","type-post","status-publish","format-standard","hentry","category-novice-en","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EU: Two new guidelines have been published and approved by the MDCG - raPHARM<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EU: Two new guidelines have been published and approved by the MDCG - raPHARM\" \/>\n<meta property=\"og:description\" content=\"Recently, two new guidelines, MDCG 2022-5 and MDCG 2022-6, were published on the website of the European Commission and approved by the Medical Devices Coordination Group (MDCG). The guidelines are drafted in collaboration with interested parties represented in the various groups and are not legally binding. They present a common understanding of how the MDR...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/\" \/>\n<meta property=\"og:site_name\" content=\"raPHARM\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-12T12:02:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-16T07:56:13+00:00\" \/>\n<meta name=\"author\" content=\"rapharm\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rapharm\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/\",\"url\":\"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/\",\"name\":\"EU: Two new guidelines have been published and approved by the MDCG - raPHARM\",\"isPartOf\":{\"@id\":\"https:\/\/www.rapharm.eu\/#website\"},\"datePublished\":\"2022-05-12T12:02:31+00:00\",\"dateModified\":\"2022-05-16T07:56:13+00:00\",\"author\":{\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.rapharm.eu\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU: Two new guidelines have been published and approved by the MDCG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rapharm.eu\/#website\",\"url\":\"https:\/\/www.rapharm.eu\/\",\"name\":\"raPHARM\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rapharm.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1\",\"name\":\"rapharm\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g\",\"caption\":\"rapharm\"},\"url\":\"https:\/\/www.rapharm.eu\/en\/author\/rapharm\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EU: Two new guidelines have been published and approved by the MDCG - raPHARM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/","og_locale":"en_US","og_type":"article","og_title":"EU: Two new guidelines have been published and approved by the MDCG - raPHARM","og_description":"Recently, two new guidelines, MDCG 2022-5 and MDCG 2022-6, were published on the website of the European Commission and approved by the Medical Devices Coordination Group (MDCG). The guidelines are drafted in collaboration with interested parties represented in the various groups and are not legally binding. They present a common understanding of how the MDR...","og_url":"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/","og_site_name":"raPHARM","article_published_time":"2022-05-12T12:02:31+00:00","article_modified_time":"2022-05-16T07:56:13+00:00","author":"rapharm","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rapharm","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/","url":"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/","name":"EU: Two new guidelines have been published and approved by the MDCG - raPHARM","isPartOf":{"@id":"https:\/\/www.rapharm.eu\/#website"},"datePublished":"2022-05-12T12:02:31+00:00","dateModified":"2022-05-16T07:56:13+00:00","author":{"@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1"},"breadcrumb":{"@id":"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rapharm.eu\/eu-objavljeni-sta-dve-novi-smernici-ki-jih-je-potrdila-mdcg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rapharm.eu\/en\/"},{"@type":"ListItem","position":2,"name":"EU: Two new guidelines have been published and approved by the MDCG"}]},{"@type":"WebSite","@id":"https:\/\/www.rapharm.eu\/#website","url":"https:\/\/www.rapharm.eu\/","name":"raPHARM","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rapharm.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1","name":"rapharm","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g","caption":"rapharm"},"url":"https:\/\/www.rapharm.eu\/en\/author\/rapharm\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/posts\/6095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/comments?post=6095"}],"version-history":[{"count":2,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/posts\/6095\/revisions"}],"predecessor-version":[{"id":6100,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/posts\/6095\/revisions\/6100"}],"wp:attachment":[{"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/media?parent=6095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/categories?post=6095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/tags?post=6095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}